Cefpodoxime

Revision as of 15:28, 6 January 2014 by Gerald Chi (talk | contribs) (Changed protection level for "Cefpodoxime" ([Edit=Allow only autoconfirmed users] (expires 15:28, 20 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 15:28, 20 January 2014 (UTC))))
Jump to navigation Jump to search
Cefpodoxime
File:Cefpodoxime.svg
Clinical data
Pregnancy
category
  • AU: B1
  • US: B (No risk in non-human studies)
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability50%
Protein binding21% to 29%
MetabolismNegligible. Cefpodoxime proxetil is metabolized to cefpodoxime by the liver
Elimination half-life2 hours
ExcretionRenal, unchanged
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H17N5O6S2
Molar mass427.458 g/mol

WikiDoc Resources for Cefpodoxime

Articles

Most recent articles on Cefpodoxime

Most cited articles on Cefpodoxime

Review articles on Cefpodoxime

Articles on Cefpodoxime in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cefpodoxime

Images of Cefpodoxime

Photos of Cefpodoxime

Podcasts & MP3s on Cefpodoxime

Videos on Cefpodoxime

Evidence Based Medicine

Cochrane Collaboration on Cefpodoxime

Bandolier on Cefpodoxime

TRIP on Cefpodoxime

Clinical Trials

Ongoing Trials on Cefpodoxime at Clinical Trials.gov

Trial results on Cefpodoxime

Clinical Trials on Cefpodoxime at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cefpodoxime

NICE Guidance on Cefpodoxime

NHS PRODIGY Guidance

FDA on Cefpodoxime

CDC on Cefpodoxime

Books

Books on Cefpodoxime

News

Cefpodoxime in the news

Be alerted to news on Cefpodoxime

News trends on Cefpodoxime

Commentary

Blogs on Cefpodoxime

Definitions

Definitions of Cefpodoxime

Patient Resources / Community

Patient resources on Cefpodoxime

Discussion groups on Cefpodoxime

Patient Handouts on Cefpodoxime

Directions to Hospitals Treating Cefpodoxime

Risk calculators and risk factors for Cefpodoxime

Healthcare Provider Resources

Symptoms of Cefpodoxime

Causes & Risk Factors for Cefpodoxime

Diagnostic studies for Cefpodoxime

Treatment of Cefpodoxime

Continuing Medical Education (CME)

CME Programs on Cefpodoxime

International

Cefpodoxime en Espanol

Cefpodoxime en Francais

Business

Cefpodoxime in the Marketplace

Patents on Cefpodoxime

Experimental / Informatics

List of terms related to Cefpodoxime


Cefpodoxime (marketed as the prodrug cefpodoxime proxetil by Pharmacia & Upjohn under the trade name Vantin®) is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment. Pfizer, the parent company of Pharmacia & Upjohn, markets Cefpodoxime proxetil under the trade name Simplicef® for veterinary use. The dose range in dogs is 5-10 mg/kg body weight, administered orally, once a day. Outside the US, Cefpodoxime proxetil is marketed as Banan®.


File:Cefpodoxime proxetil.svg
Structural formula of cefpodoxime proxetil

External links

th:เซฟโปดอกซิม


Template:WH Template:WS